Table 1.
Recombinant Ad vectors used in this study.
| Virus a | Promoter b | Transgene c | Hexon d |
|---|---|---|---|
| AdH5cmvLuc | CMV | Luc | H5 |
| AdH5RoboLuc | Robo4 | Luc | H5 |
| AdH5cmvCEA | CMV | CEA | H5 |
| AdH5RoboCEA | Robo4 | CEA | H5 |
| AdH5RoboEGFP | Robo4 | EGFP | H5 |
| AdH5/H3RoboLuc | Robo4 | Luc | H5/H3 |
| AdH5/H3cmvLuc | CMV | Luc | H5/H3 |
| AdH5*7*cmvLuc | CMV | Luc | H5*7* |
| AdH3cmvLuc | CMV | Luc | H3 |
a
Genomic regions relevant to our proposed studies are shown.
b
CMV, human cytomegalovirus enhancer/promoter; Robo4, Roundabout 4 receptor enhancer/promoter.
c
Luc, firefly luciferase; CEA, carcinoembryonic antigen; EGFP, enhanced green fluorescent protein.
d
H5, wild-type Ad serotype 5 hexon; H5/H3, Ad5 hexon with substitution the hypervariable region 7 (HVR7) from Ad serotype 3; H5*7*, Ad5 hexon with point mutations within HVR5 (T270P and E271G) and HVR7 (I421G, T423N, E424S, L426Y, and E451Q); H3, Ad3 hexon swapping.